U.S. markets closed
  • S&P 500

    4,468.00
    +7.17 (+0.16%)
     
  • Dow 30

    35,515.38
    +15.48 (+0.04%)
     
  • Nasdaq

    14,822.90
    +6.60 (+0.04%)
     
  • Russell 2000

    2,223.11
    -20.96 (-0.93%)
     
  • Crude Oil

    68.03
    -1.06 (-1.53%)
     
  • Gold

    1,781.50
    +29.70 (+1.70%)
     
  • Silver

    23.74
    +0.62 (+2.70%)
     
  • EUR/USD

    1.1792
    +0.0054 (+0.46%)
     
  • 10-Yr Bond

    1.2970
    -0.0700 (-5.12%)
     
  • GBP/USD

    1.3874
    +0.0066 (+0.48%)
     
  • USD/JPY

    109.5900
    -0.8320 (-0.75%)
     
  • BTC-USD

    46,029.68
    -747.98 (-1.60%)
     
  • CMC Crypto 200

    1,183.17
    +56.68 (+5.03%)
     
  • FTSE 100

    7,218.71
    +25.48 (+0.35%)
     
  • Nikkei 225

    27,977.15
    -37.85 (-0.14%)
     

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / August 15, 2021 / Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ:SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.comor 888-476-6529, ext. 7980.

The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 29, 2021, Cassava issued a press release entitled "Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer's Disease." Although the press release touted supposedly positive cognition data, analysts and industry observers noted that the data had not demonstrated that Simufilam was more effective at improving cognition than Biogen Inc.'s drug Aduhelm.

On this news, Cassava's stock price fell $33.82 per share, or 33.82%, to close at $69.53 per share on July 30, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP



View source version on accesswire.com:
https://www.accesswire.com/659833/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Cassava-Sciences-Inc--SAVA